Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Revue De Pneumologie Clinique|November 13, 2004
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?]J-L Pujol, W Jacot, J-L Breton, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapyP Taourel, E Pages, I Millet, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 13, 2012
[How to treat brain metastasis in 2012?]A L Braccini, D Azria, J-J Mazeron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2008
Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patientsW Jacot, B Colinet, D Bertrand, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 6, 2008
[How to combine hormonotherapy and radiation treatment in adjuvant breast cancer?]D Azria, M Ozsahin, J Gligorov, et al.
British Journal of Cancer|October 20, 2005
A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's indexB Colinet, W Jacot, D Bertrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2012
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patientsN Kluger, W Jacot, E Frouin, et al.
British Journal of Cancer|April 5, 2001
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsW Jacot, X Quantin, J M Boher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III studyW Jacot, N Firmin, L Roca, et al.
ESMO Open|May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trialX Hu, G Curigliano, K Yonemori, et al.
Pageof 4